Abstract
During the transduction of extracellular signals within the cell, the stimulation of specific G protein-coupled receptors (GPCRs) can modulate adenylyl or guanylyl cyclase, phospholipase C activity and ion channels, which regulate second-messengers. These, in turn, trigger several biochemical cascades, including Ca2+ release, activation of protein kinases and gene expression. Significant changes of monoamine GPCR activity may occur in patients suffering from mood disorders and the majority of antidepressants exert part of their effects through GPCR-mediated systems. The main signal transduction pathways activated by metabotropic receptors in the brain and their possible involvement in the pathophysiology of mood disorders will be reviewed herein with a special focus on the horizons opened by this approach in terms of innovative therapeutic strategies.
Keywords: G protein-coupled receptors, central nervous system, adenylyl cyclase, guanylyl cyclase, phospholipase C, mood disorders, antidepressants
Current Medicinal Chemistry
Title: Second Messenger Modulation: A Novel Target of Future Antidepressants?
Volume: 16 Issue: 35
Author(s): D. Marazziti, M. Catena Dell'Osso, G. Consoli and S. Baroni
Affiliation:
Keywords: G protein-coupled receptors, central nervous system, adenylyl cyclase, guanylyl cyclase, phospholipase C, mood disorders, antidepressants
Abstract: During the transduction of extracellular signals within the cell, the stimulation of specific G protein-coupled receptors (GPCRs) can modulate adenylyl or guanylyl cyclase, phospholipase C activity and ion channels, which regulate second-messengers. These, in turn, trigger several biochemical cascades, including Ca2+ release, activation of protein kinases and gene expression. Significant changes of monoamine GPCR activity may occur in patients suffering from mood disorders and the majority of antidepressants exert part of their effects through GPCR-mediated systems. The main signal transduction pathways activated by metabotropic receptors in the brain and their possible involvement in the pathophysiology of mood disorders will be reviewed herein with a special focus on the horizons opened by this approach in terms of innovative therapeutic strategies.
Export Options
About this article
Cite this article as:
Marazziti D., Dell'Osso Catena M., Consoli G. and Baroni S., Second Messenger Modulation: A Novel Target of Future Antidepressants?, Current Medicinal Chemistry 2009; 16 (35) . https://dx.doi.org/10.2174/092986709789878184
DOI https://dx.doi.org/10.2174/092986709789878184 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translating Enzymology into Metabolic Regulation: The Case of the 2- Oxoglutarate Dehydrogenase Multienzyme Complex
Current Chemical Biology Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer
Current Pharmaceutical Design Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI) Patients are Characterized by Increased BDNF Serum Levels
Current Alzheimer Research Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction
Current Alzheimer Research Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Neurobiological Evidence for the Primacy of Mania Hypothesis
Current Neuropharmacology Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Effect of Ouabain on the Immune System
Current Hypertension Reviews Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders The Era of Cerebellar Therapy
Current Neuropharmacology